US Pharma MarketingInvestigational CRISPR therapy succeeds in patient with drug-resistant E. Coli
Investigational CRISPR therapy succeeds in patient with drug-resistant E. Coli is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
The CRISPR therapy, SNIPR001, was administered to the patient who had developed E. Coli following a single-patient emergency IND.
Source: Pharmaceutical Technology